Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin +/- veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC.
Telli M, Metzger O, Timms K, Evans B, Vogel D, Wei H, Jones J, Wenstrup R, McKee M, Sullivan D, Fallstrom M, Maag D, Ansell P, Sohn J, Chen S, Martinez N, Geyer C, Loibl S, Golshan M. Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin +/- veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC. Journal Of Clinical Oncology 2018, 36: 519-519. DOI: 10.1200/jco.2018.36.15_suppl.519.Peer-Reviewed Original Research